Pivotal Phase 2b clinical trial (ELPIS II) for Lomecel-B™ has achieved over 90% enrollment and is expected to complete enrollment by Q2 2025, indicating strong progress in a rare pediatric disease ...
This article first appeared on GuruFocus. Longeveron Inc (NASDAQ:LGVN) is set to release its Q4 2025 earnings on Mar 17, 2026. The consensus estimate for Q4 2025 revenue is $0.15 million, and the ...
Longeveron Inc. CEO Wa’el Hashad to present at H.C. Wainwright Conference on June 16-17, 2025. Webcast available. Longeveron Inc., a clinical stage biotechnology company focused on regenerative ...
Good day, ladies and gentlemen, and welcome to Longeveron 2024 First Quarter Financial Results Earnings Call. [Operator Instructions] Please note that this conference call is being recorded. I would ...
Longeveron Inc. (NASDAQ:LGVN) shares are trading higher Thursday, and the stock is up more than 200% this week. Here's a look at what's going on. Longeveron shares climbed more than 150% Wednesday ...
Good morning, and welcome to Longeveron's call today to discuss the company's 2022 Fourth Quarter and Full Year Financial Results. [Operator Instructions] I would now like to turn the call over to ...
Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Longeveron ( (LGVN)) has issued an update. Longeveron Inc., a clinical-stage biotech focused on ...
Longeveron today is a more focused, capital-efficient, and strategically aligned organization. With a differentiated platform, multiple shots on goal, and a clear path to near-term value inflection, ...
Marie Washburn Marie Washburn, Longeveron CFO Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased Longeveron Inc. (NASDAQ: LGVN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results